Insulin and other treatment alternatives in gestational diabetes mellitus

Prenatal and Neonatal Medicine

Volumn 3, Issue 6, 1998, Pages 542-549

  Langer, O ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Fetal ultrasonography; Gestational diabetes; Insulin therapy; Oral hypoglycemic agents

Indexed keywords

EID: 0000801411     PISSN: 13598635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. American Diabetes Association. Gestational diabetes mellitus. American Diabetes Association: clinical practice recommendations. Diabetes Care 1998;21:S60-1
2. American College of Obstetricians and Gynecologists. Management of Diabetes Mellitus in Pregnancy, Technical Bulletin 92. Washington, DC: ACOG, 1996:1-2
3. International Workshop on Gestational Diabetes. Diabetes Care 1997;20
4. Langer O, Mazze RS. Diabetes in pregnancy: evaluating self-monitoring performance and glycemic control with memory-based reflectance meters. Am J Obstet Gynecol 1986;155:635-7
5. Langer O, Rodriguez DA, Xenakis EMJ, McFarland MB, Berkus MD, Arredondo F. Intensified vs. conventional management of gestational diabetes. Am J Obstet Gynecol 1994;170:1036-47
6. Langer O, Berkus M, Brustman L, Anyaegbunam A, Gonzales D, Mazze R. The rationale for insulin management in gestational diabetes mellitus. Diabetes 1991;40(Suppl 2):186-90
7. Langer O. Management of gestational diabetes. Clin Perinatol 1993;20:603-17
8. Langer O, Hod M. Management of gestational diabetes mellitus. Obstet Gynecol Clin North Am 1996;23:137-59
9. Langer O, Levy J, Brustman L, Anyaegbunam A, Merkatz R, Divon MY. Glycemic control in gestational diabetes mellitus - how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989;161:646-53
10. Langer O, Mazze RS. The relationshp between large-for-gestational-age infants and glycemic control in women with GDM. Am J Obstet Gynecol 1988;159:1478-83
11. Langer O. Is normoglycemia the correct threshold to prevent complications in the pregnant diabetic? Diabetes Rev 1996;4:2-10
12. Caritis S, Sibai B, Hauth J, et al. Dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med 1998;337:69-76
13. Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989;321:351-6
14. Garner P, Okun N, Keely E, et al. A randomized controlled trial of strict glycemic control and tertiary level obstetric care versus routine obstetric care in the management of gestational diabetes. Am J Obstet Gynecol 1997;176:90-5
15. National Institutes of Health. Consensus Development Conference on diet and exercise in NIDDM. Diabetes Care 1987;10:639-44
16. Henry RR, Olefsky JM. Glycemic effects of intensive caloric restriction NIDDM. J Clin Endocrinol Metab 1985;61:917-25
17. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in NIDDM. J Clin Invest 1988;82:1398-406
18. Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. J Clin Invest 1992;39:701-5
19. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989;161:415-19
20. Vinik AL, Wing RR. The good, bad, and ugly in diabetic diets. Endocrinol Metab Clin North Am 1992;21:237-79
21. Brodoff B, Hendler R. Very low calorie diets. In Bjorntorp P, ed. Obesity. Philadelphia, PA: Lippincott, 1992:683-707
22. American Diabetes Association. Gestational diabetes mellitus (position statement). Diabetes Care 1996;19(Suppl 1):S29
23. Owen J, Phelan ST, Landon MB, Gabbe SG. Gestational diabetes survey. Am J Obstet Gynecol 1995;172:615-20
24. McFarland MB, Langer O, Conway D, Berkus M. Diet therapy for gestational diabetes: how long is long enough? Obstet Gynecol 1998; in press
25. Metzger BE for the Organizing Committee. Summary and recommendations of the Third International Workshop Conference on Gestational Diabetes Mellitus. Diabetes 1991;40(Suppl 2):197-201
26. Metzger BE, Coustan DR for the Oragnizing Committee. Summary and recommendations of the Fourth International Workshop Conference on Gestational Diabetes Mellitus. Diabetes Care 1998;21:B161-7
27. Anonymous. Position statement on gestational diabetes mellitus. Am J Obstet Gynecol 1986;156:488-9
28. Oppermann W, Camerini-Davalos RA. Early diabetes during pregnancy. Diabetes Care 1975;3:465-7
29. Coustan DR, Lewis SB. Insulin therapy for gestational diabetes. Obstet Gynecol 1978;51:306-10
30. Roversi GD, Gargiulo M, Nicolini U, et al. Maximal tolerated insulin therapy in gestational diabetes. Diabetes Care 1980;3:489-94
31. Coustan DR, Imarah J. Prophylactic insulin treatment of gestational diabetes reduces the incidence of macrosomia, operative delivery, and birth trauma. Am J Obstet Gynecol 1984;150:836-42
32. Persson B, Stangenberg M, Hansson U, Nordlander E. Gestational diabetes mellitus (GDM): comparative evaluation of two treatment regimens, diet versus insulin and diet. Diabetes 1985;34:101-5
33. Philipson EH, Kalhan SC, Rosen MG, Edelberg SC, Williams TG, Riha MM. Gestational diabetes mellitus: is further improvement necessary? Diabetes 1985;34:55-60
34. Leikin E, Jenkins JH, Graves WL. Prophylactic insulin in gestational diabetes. Obstet Gynecol 1987;70:587-92
35. Weiss PM. Prophylactic insulin in gestational diabetes. Obstet Gynecol 1988;71:951-2
36. Drexel H, Bichler A, Sailer S, et al. Prevention of perinatal morbidity by tight metabolic control in gestational diabetes mellitus. Diabetic Care 1988;11:761-8
37. Thompson DJ, Porter KB, Gunnells DJ, Wagner PC, Spinnato JA. Prophylactic insulin in the mangement of gestational diabetes. Obstet Gynecol 1990;75:960-4
38. Hod M, Merlob P, Friedman S, Schoenfeld A, Ovadia J. Gestational diabetes mellitus: a survey of perinatal complications in the 1980s. Diabetes 1991;40:74-8
39. Landon MB, Gabbe SG, Sachs L. Management of diabetes mellitus and pregnancy: a survey of obstetricians and maternal-fetal specialists. Obstet Gynecol 1990;75:635-40
40. Langer O. A scientific rationale for the management of diabetes in pregnancy: recent approaches using innovative computer-based technology. Diabetes Care 1988;11:67-72
41. Langer O. Maternal glycemic criteria for insulin therapy in GDM. Diabetes Care 1998;21:B1-8
42. Langer O, Anyaegbunam A, Brustman L, Guidetti D, Mazze RS. Gestational diabetes: insulin requirements in pregnancy. Am J Obstet Gynecol 1987;157:669-75
43. Spirito A, Williams C, Ruggiero L, Bond A, McGarvey ST, Coustan D. Psychological impact of the diagnosis of gestational diabetes. Obstet Gynecol 1989;73:562-6
44. Langer N, Langer O. Emotional adjustment to diagnosis and intensified treatment of gestational diabetes. Obstet Gynecol 1994;84:329-34
45. Langer O, Langer N, Piper JM, Elliot B, Anyaegbunam A. Cultural diversity as a factor in self-monitoring blood glucose in gestational diabetes. J Assoc Acad Minority Physicians 1995;6:73-7
46. Buchanan TA, Kjos SL, Montoro MN, et al. Use of fetal ultrasound to select metabolic therapy for pregnancies complicated by mild gestational diabetes. Diabetes Care 1994;17:275-83
47. Lebovitz H, Melander A. Sulfonylureas. Basic aspects and clinical uses. In Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus. New York, NY: John Wiley, 1992:745-72
48. Melander A, Faber O, Groop L. Sulphonylurea antidiabetic drugs: update. Drugs 1989;37:58-72
49. Groop L, Luzi L, Melander A, Groop PH, DeFronzo RA. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987;36:1320-8
50. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991;14:724-7
51. DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin dependent diabetic individuals. Diabetes Care 1984;7:72-80
52. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45
53. Jackson WPU, Campbell GD, Notelovitz D. Tolbutamide and chlorpropamide during pregnancy in human diabetics. Diabetes 1962;2(Suppl):98-101
54. Douglas CP, Richards R. Use of chlorpropamide in the treatment of diabetes in pregnancy. Diabetes 1967;16:60-2
55. Dolger H, Bookman JJ, Nehemias C. The diagnostic and therapeutic value of tolbutamide in pregnant diabetics. Diabetes 1962;11(Suppl):97-8
56. Notelovitz, M. Sulfonylurea therapy in the treatment of the pregnant diabetic. S Afr Med J 1971;45:226-9
57. Stowers JM, Sutherland HW. The use of sulphonylureas biguanides and insulin in pregnancy. In Sutherland HW, Stowers JM, eds. Carbohydrate Metabolism in Pregnancy and the Newborn. London: Churchill Livingstone, 1975;205-20
58. Sutherland HW, Bewsher PD, Cormack JD, et al. Effect of moderate dosage of chlorpropamide in pregnancy on fetal outcome. Arch Dis Childh 1974;49:283-91
59. Coetzee EJ, Jackson WPU. Pregnancy in established non-insulin-dependent diabetics. S Afr Med J 1980;58:795-802
60. Coetzee EJ, Jackson WPU. Oral hypoglycaemics in the first trimester and fetal outome. S Afr Med J 1984;65:635-7
61. Coetzee EJ, Jackson WPU. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1986;1:281-7
62. Velasco MSA, Paulsen EP. The response of infants of diabetic women to tolbutamide and leucine at birth, and to glucose and tolbutamide at 2 years of age. Pediatrics 1969;43:546-57
63. Kemball ML, Mclver C, Milner RDG, Nourses CH, Schiff D, Tiernan JR. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970;45:696-701
64. Jorfar JO, Nelson MM. Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther 1975;14:632-42
65. Hollingsworth PK, Murphy H. Effects of in-utero exposure to oral hypoglycemic drugs. Lancet 1991;338:866-9
66. Anonymous. Prolonged symptomatic nenonatal hypoglycemia associated with maternal chlorpropamide therapy. Pediatrics 1968;42:824
67. Elliot B, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991;165:807-12
68. Elliot B, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents. A model of human placental drug transfer. Am J Obstet Gynecol 1994;171:653-60
69. Elliot B, Langer O, Schuessling F. A model of human placental drug transfer. Am J Obstet Gynecol 1997;176:527-30
70. Sivan E, Feldman B, Dolitzki M, et al. Glyburide crosses the placenta in vivo in pregnant rats. Diabetologia 1995;38:753-6
71. Smithberg M, Runner MN. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am J Anat 1963;113:479-89
72. Smoak IW. Teratogenic effects of chlorpropamide in mouse embryos in vitro. Teratology 1992;45:474
73. Denno KM, Saddler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology 1994;49:260-6